Gamgee's AI dog cancer vaccine startup claims 75% tumor reduction

Paul Conyngham, an Australian tech entrepreneur who openly admits he is "not a biologist," has turned his viral AI-saved-my-dog story into a startup called Gamgee. The company offers personalized mRNA cancer vaccines for dogs, powered by AI tools like ChatGPT, Grok, and computational genomics. Its origin story centers on Rosie, Conyngham's Staffordshire bull terrier-Shar Pei mix, whose tumors purportedly shrank after receiving a vaccine he designed with AI. Gamgee's website promises to deliver a finished vaccine in about four weeks, requires less than 20 minutes of a veterinarian's time, and claims a roughly 75 percent tumor reduction in its "first documented case." The startup is recruiting for its first clinical trials in Australia, with collaborations involving the University of Queensland and the University of New South Wales.

However, the science behind Rosie's recovery is far from settled. As The Verge reported earlier this year, the exact role AI played was unclear, and the vaccine was administered alongside another therapy, making it impossible to attribute her improvement to the mRNA vaccine alone. Researchers warned that broad claims overstate AI's contribution and downplay human expertise. Despite these concerns, Gamgee has secured backing from famed accelerator Y Combinator. The company's ambitions extend well beyond dogs—its website promises to eventually develop personalized treatments for a range of diseases and species, including humans. For a startup built around a single anecdote with unproven biology, that's a grand leap from a single dog to systemic medical breakthroughs.